Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Hexetidine→

Hexetidine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
141-94-6
Molecular formula
C21H45N3
Molecular weight
339.6 g/mol
Drug class
Cationic topical antisepticlocal anti-infective agent
Mechanism of action
A cationic antiseptic with broad antimicrobial activity. It interacts with microbial cell surfaces and membrane-associated systems, producing bacteriostatic or bactericidal effects depending on concentration and organism.
Indications / reported uses
  • Local treatment and prevention of infections of the mouth and oropharynx and support of oral hygiene with labelled mouthwash or spray formulations.
  • Topical antiseptic use on skin or in veterinary preparations where specifically authorised.

Sources: https://www.ema.europa.eu/en/documents/mrl-report/hexetidine-summary-report-committee-veterinary-medicinal-products_en.pdf · https://pubchem.ncbi.nlm.nih.gov/compound/3607 · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Hexetidine Environmental Risk Assessment (ERA) (the Hexetidine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.